D-Ethyl 1-(3-((tert-Butoxy)carbonylamino)propyl)-4-oxo-7-(((1-(triphenylmethyl)imidazole-2-yl)amino)methyl)hydroquinoline-3-carboxylate | 277315-99-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: D-Ethyl 1-(3-((tert-Butoxy)carbonylamino)propyl)-4-oxo-7-(((1-(triphenylmethyl)imidazole-2-yl)amino)methyl)hydroquinoline-3-carboxylate
• 英文别名: Ethyl 1-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4-oxo-7-[[(1-tritylimidazol-2-yl)amino]methyl]quinoline-3-carboxylate
• CAS: 277315-99-8
• 化学式: C₄₃H₄₅N₅O₅
• 分子量: 711.861
• InChiKey: PPCAWQSIRUAPJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  53
• 可旋转键数：
  16
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  Na(OAc)3BH 、 1-trityl-2-aminoimidazole 生成 D-Ethyl 1-(3-((tert-Butoxy)carbonylamino)propyl)-4-oxo-7-(((1-(triphenylmethyl)imidazole-2-yl)amino)methyl)hydroquinoline-3-carboxylate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Vitronectin receptor antagonist pharmaceuticals
  申请人：——

  公开号：US20020041878A1

  公开（公告）日：2002-04-11

  The present invention describes novel compounds of the formula: (Q) d -L n -C h , useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

  本发明描述了式中的新型化合物： (Q) d -L n -C h , 用于诊断和治疗癌症、患者肿瘤成像方法和患者癌症治疗方法。本发明还提供了用于监测治疗性血管生成治疗和新血管生成血管破坏的新型化合物。本发明进一步提供了用于动脉粥样硬化、再狭窄、心脏缺血和心肌再灌注损伤成像的新型化合物。本发明还进一步提供了用于治疗类风湿性关节炎的新型化合物。这些药物由与血管生成过程中上调的受体结合的靶向分子、任选连接基团和治疗有效的放射性同位素或诊断有效的可成像分子组成。可成像分子是伽马射线或正电子发射的放射性同位素、磁共振成像造影剂、X 射线造影剂或超声造影剂。
• EP1307226B1
  申请人：——

  公开号：EP1307226B1

  公开（公告）日：2008-11-19
• VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1307226A2

  公开（公告）日：2003-05-07
• US7138104B2
  申请人：——

  公开号：US7138104B2

  公开（公告）日：2006-11-21
• [EN] VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY<br/>[FR] AGENTS PHARMACEUTIQUES ANTAGONISTES DU RECEPTEUR DE VITRONECTINE, A UTILISER EN POLYTHERAPIE
  申请人：DU PONT PHARM CO

  公开号：WO2001097848A2

  公开（公告）日：2001-12-27

  The present invention describes novel kits and compositions comprising compounds of the formula (I): (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.